Investor Ideas #Potcasts;
#Cannabis News and #Stocks on the Move: Special Interview with Trevor Peters of
Willow Biosciences (CSE: $WLLW.C) (OTC: $CANSF)
Delta, Kelowna, BC –July 30, 2019 (Investorideas.com
Newswire) www.Investorideas.com, a global news source covering leading sectors
including marijuana and hemp stocks and its potcast site, www.potcasts.ca
release today’s edition of Investorideas.com
potcastsCM - cannabis news and stocks to watch plus insight from
thought leaders and experts.
Listen to the podcast:
Read this in full at
In
today’s podcast we interview Trevor Peters, President and CEO of Willow Biosciences Inc. (CSE: WLLW) (OTC: CANSF), regarding the company’s
entrance into the cannabinoid space, some of their recent developments as well
as the future of the CBD market.
Mr.
Peters has co-founded four start-up companies in the past 15 years and raised
over $1.0 billion in equity and debt financing at various stages of corporate
development and has been integral to successful transactions totalling over
$4.0 billion on sale. Mr. Peters previously was Chief Financial Officer at
Caracal Energy Inc., which sold to Glencore plc in 2014 for $1.8 billion.
Willow Biosciences was founded in 2019 through the merger of BIOCAN
Technologies: a team of experienced executives from Calgary and researchers
from the University of British Columbia, and Epimeron: a team of researchers
from the University of Calgary in Alberta, Canada.
The
company has developed the only fully-integrated synthetic biology solution for
opiate biosynthesis and are now leveraging their unique design-build
process–and our proven track record–to the biosynthesis of cannabinoids.
We
discussed the company’s last announcement of their partnership with Noramco to collaboratively develop a
yeast-based biosynthesis platform for the production and distribution of CBD.
“Noramco sees the market the same way we
do. There selling about 1 tonne of CBD into the pharmaceutical market. Once we
see descheduling in the US, we will see them selling more broadly into those
markets. Noramco currently uses chemical synthesis which is more expensive then
our process which is why they’ve partnered with us exclusively. They view our
process as being roughly 80% more cost effective then their existing processes.
Noramco is important to us because they’re one of the world’s most
sophisticated and largest manufacturers of controlled substances and API’s and
they already have a very large customer base.”
Trevor also expressed the company’s interest
in exploring the culturing of other cannabinoids in the future such as CBG, THC
and THCV.
Trevor also discussed the major differences
between his company which biosynthetically cultures plant molecules and the
plant cultivation and extract community and some of the benefit of cultured CBD
versus plant extracted molecules.
“Our CBD molecule is the same as the one
the plant produces, except when we produce it it’s just CBD, and is obviously
very high purity from that perspective. It’s consistent. There’s no extract
process, or other distillation process associated with it, it comes out in the
final form. It’s very usable in whatever market might be required.”
Willow Biosciences is not the only
company looking into cultured CBD as we saw mostly recently from Cronos Group (NASDAQ:
CRON) (TSX:CRON) and
their announcement to
enter into an agreement to acquire GMP compliant fermentation and manufacturing
facility from Apotex Fermentation. This follows Cronos Grouppartnership with
Ginkgo Bioworks with the aim to produce cultured cannabinoids and with this new
facility addition, the company would be able to achieve that at a commercial
scale.
When asked about the future of Willow
Biosciences Trevor commented, “over the next 6 to 12 months we are going to be
working on the hardcore science, developing a new strain and being able to take
it to scale and manufacturing. Since the Noramco announcement we’ve seen a lot
of interest from companies that are interested in accessing CBD at scale. We’ve
also seen other interests from people in the pharmacological community looking
at minor cannabinoids as well.”
Investor ideas reminds all listeners to read our disclaimers and
disclosures on the
Investorideas.com website and this podcast is not an endorsement
to buy products or services or securities. Investors are reminded all investment
involves risk and possible loss of investment
Subscribe to the new cannabis podcast series:
Investorideas.com podcasts are also available
on iTunes, Spotify, Google Play Music,
Stitcher, Spreaker, YouTube via
Spreaker, iHeartradio and Tunein.
Potcasts is now a certified word mark Trademark
on the blockchain through Cognate, Inc. CM Certification-Registration Number:
10468217708
About Investorideas.com - News that Inspires Big Investing Ideas
Investorideas.com is a recognized news
source publishing third party news and press releases plus we create original
financial content. Learn about investing in stocks and sector trends
from Investorideas.com with our news alerts , articles , podcasts and videos talking about cannabis, crypto,
technology including AI and IoT ,
mining ,sports biotech, water, renewable energy and more . Investorideas.com
original branded content includes the daily Crypto Corner and Podcast, Play
by Play sports and stock news column, Investor Ideas #Potcasts #Cannabis News
and Stocks on the Move podcast and column,
Cleantech and Climate Change Podcast and
the AI
Eye Podcast and column covering developments in
AI.
Disclaimer/Disclosure: Investorideas.com is a
digital publisher of third party sourced news, articles and equity research as
well as creates original content, including video, interviews and articles.
Original content created by investorideas is protected by copyright laws other
than syndication rights. Our site does not make recommendations for purchases
or sale of stocks, services or products. Nothing on our sites should be
construed as an offer or solicitation to buy or sell products or securities.
All investing involves risk and possible losses. This site is currently
compensated for news publication and distribution, social media and marketing,
content creation and more. Disclosure is posted for each compensated news
release, content published /created if required but otherwise the news was not
compensated for and was published for the sole interest of our readers and
followers. Contact management and IR of each company directly regarding
specific questions.
More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn
more about publishing your news release and our other news services on the
Investorideas.com newswire https://www.investorideas.com/News-Upload/ and
tickertagstocknews.com
Global investors must adhere to regulations of each
country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp
Investor Ideas does not condone the use of cannabis except where
permissible by law. Our site does not possess, distribute, or sell cannabis
products.
Follow us on Social Media
Contact Investorideas.com
800-665-0411
No comments:
Post a Comment